Acepodia

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies...

Oncology,cancer cell immunotherapy,allogeneic,off-the-shelf,nk cells,biotechnology,interdisciplinary technology,car,and cell therapy

Acepodia operates in the Biotechnology research industry.

Acepodia's revenue is 11m - 100m

Acepodia has 11 - 50 employees.